Area Drugs and Therapeutics Committee Meeting Minutes Wednesday 20th September 2023 @10am Microsoft Teams Meeting		
Present:	Mehrdad Malekian MM (Chair) Victoria Gemmell VG (Sec) Stephanie Dundas SD Penny Brankin PB Kelly Baillie KB (items 10,12) Tyra Smyth TS Emma Harris EH Carol McGoff CM Gail Richardson GR	Kirsty Macfarlane KM Caroline Mclean CM David Semple DS (until item
Apologies:	**nil**	
Declaration of Interest	**nil**	

Item	Notes	Action
3	**<u>Minutes/Actions from the last meeting</u>** Some comments were received. These will be carried over to the next meeting	VG/GR
4	**<u>Matters Arising</u>**	
a.	Ogluo-nil further received MM to get back in touch with author	MM
b.	IV Contrast-update Author requested to add info around repeat TFT's and return for final agreement	MM
c.	Bijuve-nil further received VG to get back in touch with author	VG
d.	Utrogestan-nil further received VG to get back in touch with author	
e.	Croup-update This was agreed	
f.	PPI in Neonates and children update This was agreed	
g.	Psoriasis and Eczema Pathways-update These were discussed. There was a request to add specific info for primary care around sharing specific drug name, dose and interval.	VG

h.	IV Fluids This is ongoing. The document is with Medical Illustration. Will be returned once reformatted ED consultants have also been consulted	
i.	Opioid Update/CD poster Still under discussion. Remove from agenda at present	
j.	Topical Retinoids-Update KM gave an update. Group would prefer briefer version. To be finalized over email and returned for final agreement	KM
k.	Massive PE Guidance-Update Expected in October	MM
5	**SMC Advice-CONFIDENTIAL** Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website **after 10.00 am** on **Monday 09 October 2023.** **Full Submissions** • olaparib (Lynparza) AstraZeneca UK Ltd SMC2518 **Accepted with PAS FOR NOTING** • fenfluramine (Fintepla) UCB Pharma Ltd SMC2569 **Accepted with PAS Currently in use. To be discussed with finance in Primary Care. GR to take forward.** • regorafenib (Stivarga) Bayer plc SMC2562 **Accepted with PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance.** • brexucabtagene autoleucel (Tecartus) Gilead Sciences Ltd SMC2548 **Accepted with PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance.** • belzutifan (Welireg) Merck Sharp & Dohme (UK) Limited SMC2587 **Accepted with PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance.** • voclosporin soft capsule (Lupkynis®) Otsuka Pharmaceutical (UK) Ltd SMC2570 **Accepted with PAS Refer to Renal service for comment** • maribavir film-coated tablets (Livtencity®) Takeda UK Ltd SMC2576 **Accepted with PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance.** **Resubmission** • darolutamide (Nubeqa) Bayer plc SMC2604 **Accepted with PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance.** **Ultra Orphan** **nil**	

	Abbreviated Submissions • atogepant tablets (Aquipta®) AbbVie Ltd SMC2599 **Accepted Restricted with PAS Refer to neurology. CG is taking forward discussions around treatment at tertiary services** • zanubrutinib 80 mg hard capsules (Brukinsa®) BeiGene UK Ltd SMC2600 **Accepted Restricted with PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance.** **Deferred Advice** semaglutide (Wegovy) Novo Nordisk SMC2497 **Refer to weight management service for advice** lutetium (177Lu) vipivotide tetraxetan solution for injection or infusion (Pluvicto®) Advanced Accelerator Applications SMC2517 **Not recommended- FOR NOTING** **Amended Advice** vutrisiran 25mg solution for injection in prefilled syringe (Amvuttra®) Alnylam Pharmaceuticals SMC2596 **FOR NOTING** **NICE and SMC collaboration on multiple technology appraisal for cystic fibrosis** This has been shared with Paediatric pharmacist for information **Paediatric Licence Extensions** Shared with Paediatrics pharmacist and clinical lead for Paediatrics	

Product	Formulation	Company	Paediatric indication	CHMP positive opinion[1]	Availability in UK[2]	Adults/old group
						SMC advice
baricitinib (Olumiant)	2mg and 4mg film-coated tablet	Eli Lilly & Company Ltd	Treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs):	311719/2023 (20 Jul-23)	Expected Oct-23	Accepted Restricted 1265/17
riociguat (Adempas)	0.5mg, 1mg, 1.5mg, 2mg, 2.5mg film-coated tablets	MSD	Treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 6 to less than 18 years of age and bodyweight ≥50 kg with World Health Organization (WHO) Functional Class (FC) II to III in combination with endothelin receptor antagonist (tablet formulation) Treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 6 to less than 18 years of age with World Health Organization (WHO) Functional Class (FC) I to III in combination with endothelin receptor antagonists with or without prostanoids (oral formulation)		Expected Q3, 2023	Accepted Restricted 1056/15
risdiplam (Evrysdi)	0.75mg/mL powder for oral solution	Roche Products Ltd	Treatment of 5q spinal muscular atrophy (SMA) in patients under 2 months of age with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies	807714/2022 (20 Jul-23)	Expected Sep-23	Accepted SMC2401

6	**SMC follow up** Empagliflozin and dapagliflozin were both discussed and the Committee agreed to request guidance on use of these medicines in patients with left ventricular ejection fraction >40%. Feedback on a number of other items is expected in due course. Outstanding SMC medicines decisions for the Board were also discussed. Clarity was sought and provided from the Committee regarding these. The relevant bulletins will be updated to reflect NHS Lanarkshire's position on these medicines.	CM
7	**Lanarkshire Formulary** The first amendment proposed was to amend the preferred biosimilar of adalimumab from Amgevita® to Hyrimoz®. **POST MEETING NOTE** – informed by NHS Lanarkshire Homecare service that move to Hyrimoz® is not going ahead due to issues in the supply chain– amendment not actioned at present. The second was the addition of Insupen Original® pen needles. The third was an update to the Lanarkshire Gluten Free Foods Formulary. The above amendments were ratified by the Committee. An update to the Drugs Used in Nausea and Vertigo was presented. Some further work is needed. CM to liaise with palliative care team regarding the use of levomepromazine.	CM
8 **(a)**	**Clinical Protocols** **Antipsychotic in Dementia Review Guidance** This is an update to current guidance. This was agreed by the group.	

(b)	**Clinical Protocol-Kilsyri for Actinic Keratosis** This was discussed and comments include • Confirm where this sits in treatment pathway. A guidance document would be helpful • Clarify who will be making the diagnosis/recommendation- GP or Specialist care • Is there any patient follow up required and who will carry this out	VG
(c)	**Renal-Clinical Protocols Patiromir (Veltassa), sodium zirconium (Lokelma) and Hyperkalaemia and potassium lowering Guidelines** This was discussed and well received. A few points were noted • Merge old and new guidance documents • Any Latin terms should be in English. Some typos, and need to add units of measurement to the flowcharts. Insulin *and* Actrapid should be stated • There was also a request to include clarification of next steps on discharge of patients, detailing actions taken to address underlying causes and follow up required • Lokelma-unlicensed use-what would this be? SMC only covers licensed use • CKD/HF- Position of SCZ and patiromir needs clarified-is there a preference?	VG
(d)	**Deprescribing Guideline-additional document awaited** This was discussed and noted as a helpful document. Some comments include • Needs to be clearer it's for both Primary and Secondary Care • Detail the need for an open conversation with patient/carer/NOK that deprescribing is necessary as life expectancy is reduced • Ensure prognosis is clearly documented • Remove names and approval dates from front page as these are detailed elsewhere It is hoped that it will be shared widely	
9.	**<u>ADTC New Medicines Decisions</u>** These were noted.	

10.	**<u>Unlicensed Medicines</u>**	
(a)	Sekukinumab-for noting	
(b)	Epoetin beta and Darbepoietin-blanket request Currently included in current clinical management guidelines. Blanket approval would replace individual patient requests These need to be on separate forms These were agreed pending this and updated signatories	KB/ MM
(c)	anti-thrombin-blanket request Currently included in current protocol for management of anti-thrombin deficiency. Blanket approval would replace individual patient requests This was agreed pending updated signatories	KB/ MM
11	**<u>Medication and Clinical risk in Lanarkshire</u>** <u>https://www.gov.uk/drug-safety-update</u> nil	
12	**<u>Regional Cancer Advisory Network</u>** KB gave a summary of advice received from the regional WoScan Prescribing Advisory Subgroup for August. Of the selection, 4 will be used in NHSL. The others would be given at the tertiary centre. The advice from RCAG and NCMAG (off-label/unlicensed indications) was accepted. WoScan have updated several guidelines, including supportive medicines and clinical management guidelines for a variety of conditions. These were accepted by the group	
13	**<u>Patient Safety Alerts</u>** nil	
14.	**<u>Lay member related items</u>** nil	
15.	**<u>Correspondence</u>**	
(a)	**<u>ADTC Collaborative</u>**	
(i)	Homecare Review This will be taken forward by the Homecare Team	
(ii)	Valproate Learning VG gave feedback to the group	
16.	**Pharmacy & NMAHP Prescribing Governance** nil	

17.	**<u>AOCB</u>** nil	
18.	**<u>Date of next meeting</u>** Wednesday 18th October 2023 10-12:30 MS TEAMS	